FindTrial
Sign In

A comparative effect of Lekhaniya Mahakashaya Ghan Vati and Mustadi Ghan Vati in the management of Dyslipidemia

A comparative clinical study on Lekhaniya Mahakashaya Ghan Vati and Mustadi Ghan Vati in the management of Dyslipidemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/01/007642
Enrollment
30
Registered
2017-01-06
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E782- Mixed hyperlipidemia

Interventions

Intervention1: GROUP A - LEKHANIYA MAHAKASHAYA GHAN VATI: DOSE-6 Ghan vati(500mg each) two times a day before meal i.e. 6gm per day. ANUPAN - lukewarm water. DURATION- 6 weeks Control Intervention1:

Sponsors

Govt Akhandanand Ayurved College and Hospital Bhadra Ahmedabad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.If any one or many parameters among lipid profile of an individual found to be in limit stated below,then the subject will be included in the study for objective criteria: Serum cholesterol - 200mg/dl or more Serum triglycerides -150mg/dl or more Serum LDL - 100mg/dl or more Serum VLDL-10-30mg/dl or more Serum HDL - 2.Patient’s ongoing anti-hyperlipidemic drugs will be stopped and wash out period will be specified. 3.The main signs and symptoms in the present study will be taken for subjective criteria are as follows- weakness, Fatigue, Paraesthesia, Weight gain, Angachalatva, Alasya, Kshudrashwas, Nidradhikya, Swedadhikya, Daurgandhya , Snigdhata, Atipipasa, Atikshudha, Angagaurava.

Exclusion criteria

Exclusion criteria: •Patient having age 60 yrs. •Patient having serious cardiac problems- M.I., Cardiac Failure. •Endocrinal disorders will not be taken for study like diabetes mellitus, hypothyroid. •Patient having history of obesity and Hyperlipidemia due to drugs e.g. corticosteroids, Antidepressent drugs will not be taken for study. •If Lipid profile parameters will come in “very high range, patient will be excluded which is given below- Serum cholesterol- >300mg/dl. Serum triglycerides- >500mg/dl. Serum LDL - >190mg/dl.

Design outcomes

Primary

MeasureTime frame
After completion of the course of the treatment the result will be assessed on the basis of - lipid profile of patients before and after treatment and difference in the score of sign and symptoms of Medoroga and dyslipidemia.Timepoint: 6 weeks—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactRajneesh Pathak

Govt Akhandanand Ayurved college Ahmedabad

dhanvantari4386@gmail.com09428241982

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026